Analyst firms · Barclays · BMY
Barclays BMY price target and rating history
Bristol-Myers Squibb Company (BMY) · Health Care
Barclays rates Bristol-Myers Squibb Company (BMY) Overweight with a $75 price target, as of its latest action on Feb 20, 2026. It has published 4 rating actions on BMY since October 2021, including 0 upgrades and 1 downgrade. Across 8 firms with a BMY price target in the last 12 months, the median target is $61.50. Barclays's $75 is 22% above that.
- Current rating
- Overweight
- Price target
- $75
- Median target, all firms
- $61.50
- Actions on BMY
- 4
Barclays price target on BMY
Every Barclays rating on BMY
- Feb 20, 2026
- Jul 29, 2024
- Oct 28, 2021
- Oct 8, 2021
How other firms rate BMY
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Leerink Partners | Market Perform | $59 | Oct 5, 2026 |
| Argus Research | Buy | $75 | Aug 5, 2026 |
| RBC Capital Markets | Sector Perform | $60 | Feb 25, 2026 |
| Barclays | Overweight | $75 | Feb 20, 2026 |
| UBS | Buy | $65 | Jan 7, 2026 |
| BofA Securities | Buy | $61 | Dec 15, 2025 |
| Guggenheim | Buy | $62 | Dec 12, 2025 |
| Scotiabank | Sector Perform | $45 | Nov 13, 2025 |
Questions about Barclays and BMY
- What is Barclays's price target for BMY?
- Barclays's latest stated price target for Bristol-Myers Squibb Company (BMY) is $75, from its action on Feb 20, 2026.
- What is Barclays's rating on BMY?
- Barclays rates BMY Overweight, a bullish rating, as of Feb 20, 2026.
- When did Barclays last change its view on BMY?
- On Feb 20, 2026, Barclays starts coverage at Overweight, price target $75.
- How does Barclays's BMY target compare with other analysts?
- Across 8 firms with a BMY price target in the last 12 months, the median target is $61.50. Barclays's $75 is 22% above that.
More BMY rating histories
All Barclays ratingsBMY news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.